Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ronacaleret HCl (SB-751689) 是一种小分子 CaSR 拮抗剂,可用于治疗内分泌与代谢疾病、皮肤和肌肉骨骼疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,010 | 现货 | ||
5 mg | ¥ 4,930 | 现货 | ||
10 mg | ¥ 6,900 | 现货 | ||
25 mg | ¥ 9,870 | 现货 | ||
50 mg | ¥ 13,800 | 现货 | ||
100 mg | ¥ 18,800 | 现货 | ||
500 mg | ¥ 37,900 | 6-8周 |
产品描述 | Ronacaleret HCl (SB-751689) is a small molecule CaSR antagonist for the treatment of endocrine and metabolic diseases, skin and musculoskeletal disorders. |
体内活性 | For 569 postmenopausal women with low BMD offered open-label 20 μg teriparatide sc once daily or were randomized to 100, 200, 300, or 400 mg oral Ronacaleret HCl once daily, 70 mg alendronate once weekly, or placebo and were followed for up to 12 months.Results: With Ronacaleret HCl, the increases in lumbar spine BMD at 12 months (0.3-1.6%) were significantly lower than those attained with teriparatide (9.1%) or alendronate (4.5%). There were small decreases in total hip, femoral neck, and trochanter BMD at month 12 with Ronacaleret HCl compared with increases in the teriparatide and alendronate arms. Bone turnover markers increased in the Ronacaleret HCland teriparatide arms and decreased in the alendronate arm. PTH elevations with Ronacaleret HCl were prolonged relative to those previously reported with teriparatide. Conclusion: The densitometric findings in the context of prolonged PTH elevation and increased bone turnover suggest Ronacaleret HClinduces mild hyperparathyroidism. Ronacaleret HCl only modestly increased lumbar spine BMD and decreased BMD at hip sites.[1] |
别名 | SB 751689, SB 751689A, SB-751689A, SB-751689, SB751689A, SB751689 |
分子量 | 483.98 |
分子式 | C25H32ClF2NO4 |
CAS No. | 702686-96-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 1mg/ml, Sonication is recommended.
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ronacaleret HCl 702686-96-2 GPCR/G Protein CaSR SB 751689 SB 751689A SB-751689A SB-751689 SB751689A SB751689 Inhibitor inhibitor inhibit